NCT03059667 - Immunotherapy as Second-line in Patient With Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 13, 2017

Primary Completion Date

September 10, 2018

Study Completion Date

December 1, 2020

Conditions

Small Cell Lung CancerSmall Cell Lung Cancer Limited StageSmall Cell Lung Cancer Extensive Stage

Interventions

DRUG

Atezolizumab

Atezolizumab at 1200 mg IV every 3 weeks

DRUG

Topotecan

oral 2.3 mg/m² or IV 1.5 mg/m² day 1-4 recommended

DRUG

Carboplatin

In accordance with the summary of product characteristics.

DRUG

Etoposide

In accordance with the summary of product characteristics.

Trial Locations (18)

34295

Montpellier - CHRU, Montpellier

49000

Angers - CHU, Angers

68000

Mulhouse - CH, Mulhouse

69495

HCL - Lyon Sud (Pneumologie), Pierre-Bénite

72000

Centre Hospitalier - Pneumologie, Le Mans

74100

Annemasse - CH, Ambilly

75020

AP-HP Hopital Tenon - Pneumologie, Paris

75877

APHP - Paris Bichat, Paris

76000

Rouen - CHU, Rouen

Unknown

CH, Colmar

CHRU Grenoble, Grenoble

Lorient - CHBS, Lorient

Centre Antoine Lacassagne, Nice

GH Paris Saint-Joseph, Paris

CHG de Pau, Pau

Centre Hospitalier, Saint-Quentin

Toulouse - CHU Larrey, Toulouse

CHU Tours - Pneumologie, Tours

All Listed Sponsors

lead

Intergroupe Francophone de Cancerologie Thoracique

OTHER